We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can New Products and Acquisitions Revive Pfizer's Growth Story?
Read MoreHide Full Article
Key Takeaways
Pfizer's new and acquired products generated $3.8 billion in Q3 revenues, growing 32% operationally.
Padcev sales rose 38% to 9M, while Nurtec revenues climbed 29%, boosting Pfizer's acquired product portfolio.
Pfizer expects new products and its pipeline to drive a return to growth from 2029.
Pfizer's (PFE - Free Report) business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches and strategic acquisitions like Seagen, Metsera and Biohaven.
Its investments in acquisitions and internal research are beginning to deliver results, helping offset declining revenues from older products.
Pfizer’s newly launched and acquired products delivered $3.8 billion in revenues in the third quarter and grew 32% operationally, reflecting strong contributions from products such as Padcev, Nurtec and Lorbrena. While Padcev and Nurtec were added from the acquisitions of Seagen in 2023 and Biohaven in 2022, respectively, Lorbrena is an internally developed product. Its launched and acquired products rose 22% operationally in the first quarter and 18% in the second quarter. Pfizer is investing in these products to mitigate its upcoming loss of exclusivity (LOE) headwinds.
Pfizer's In-House Pipeline Delivers New Growth Drivers
Some internally developed product launches over the past few years were Abrysvo, an RSV vaccine approved for older adults and for maternal immunization to protect infants; Hympavzi, a once-weekly treatment for hemophilia A or B with or without inhibitors, Elrexfio, a BCMA-targeted bispecific antibody for relapsed or refractory multiple myeloma and Litfulo, for severe alopecia areata.
During the first nine months of 2026, Abrysvo generated worldwide revenues of $691 million, up 25% year over year, while Elrexfio recorded sales of $252 million, up 9%. Pfizer does not separately disclose revenues for Hympavzi and Litfulo. Additionally, the company launched Zavzpret, a nasal spray CGRP receptor antagonist for the acute treatment of migraine, in 2023, following its acquisition of the product through the Biohaven transaction in 2022.
PFE’s Acquisitions Complement Internal R&D
Seagen, Metsera and Biohaven are the most significant strategic acquisitions in recent years. These acquisitions are turning out to be transformative opportunities for the company. Padcev, added from Seagen, contributed almost $2 billion to Pfizer’s total revenues in the first nine months of 2026, up 38% on an operational basis.
Biohaven has also been a strategically important addition for Pfizer. Year to date, Nurtec revenues have risen 29% to $11.3 billion, driven by demand growth.
Overall, revenues from Pfizer’s acquired products grew 37% operationally in the third quarter.
The November 2025 acquisition of obesity drugmaker Metsera added novel clinical-stage incretin and amylin programs, which are expected to generate billions of dollars in peak sales. A key candidate added from the Metsera deal is berobenatide.
Berobenatide is being developed for weekly and monthly dosing for obesity and obesity-related conditions, including knee osteoarthritis and obstructive sleep apnea. Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. However, in the obesity space, Pfizer lags behind leaders like Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) .
The currently available and highly popular weight loss GLP therapies, Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, are weekly injections. On the other hand, Pfizer’s berobenatide starts off as a weekly injection and then switches to a monthly injection. Berobenatide is designed for monthly maintenance dosing.
Will Pfizer's New and Acquired Drugs Fuel Future Growth?
Overall, Pfizer's new and acquired products are gradually changing its growth story from one heavily influenced by COVID-19 revenues to a more diversified business driven by oncology, specialty medicines, vaccines and migraine treatments.
Pfizer expects its recently launched and acquired products and a strong pipeline to help it return to growth from 2029 onward. Pfizer expects a risk-adjusted high single-digit revenue CAGR toward the end of the decade — from year-end 2028 through year-end 2033.
Newer products are becoming increasingly important to the company's long-term growth, although their gains have not yet translated into strong overall revenue growth.
PFE’s Price Performance, Valuation and Estimates
Pfizer’s stock has risen 12.9% so far this year compared with an increase of 24.2% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry. Going by the price/earnings ratio, Pfizer’s shares currently trade at 9.45 forward earnings, significantly lower than 19.50 for the industry but slightly above the stock’s five-year mean of 9.25. The stock is also trading below most large drugmakers like Lilly, Novo Nordisk, AstraZeneca, AbbVie, J&J and others.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has risen from $2.95 to $3.01, while that for 2027 has risen from $2.95 to $2.96 over the past 30 days.
Image: Bigstock
Can New Products and Acquisitions Revive Pfizer's Growth Story?
Key Takeaways
Pfizer's (PFE - Free Report) business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches and strategic acquisitions like Seagen, Metsera and Biohaven.
Its investments in acquisitions and internal research are beginning to deliver results, helping offset declining revenues from older products.
Pfizer’s newly launched and acquired products delivered $3.8 billion in revenues in the third quarter and grew 32% operationally, reflecting strong contributions from products such as Padcev, Nurtec and Lorbrena. While Padcev and Nurtec were added from the acquisitions of Seagen in 2023 and Biohaven in 2022, respectively, Lorbrena is an internally developed product. Its launched and acquired products rose 22% operationally in the first quarter and 18% in the second quarter. Pfizer is investing in these products to mitigate its upcoming loss of exclusivity (LOE) headwinds.
Pfizer's In-House Pipeline Delivers New Growth Drivers
Some internally developed product launches over the past few years were Abrysvo, an RSV vaccine approved for older adults and for maternal immunization to protect infants; Hympavzi, a once-weekly treatment for hemophilia A or B with or without inhibitors, Elrexfio, a BCMA-targeted bispecific antibody for relapsed or refractory multiple myeloma and Litfulo, for severe alopecia areata.
During the first nine months of 2026, Abrysvo generated worldwide revenues of $691 million, up 25% year over year, while Elrexfio recorded sales of $252 million, up 9%. Pfizer does not separately disclose revenues for Hympavzi and Litfulo. Additionally, the company launched Zavzpret, a nasal spray CGRP receptor antagonist for the acute treatment of migraine, in 2023, following its acquisition of the product through the Biohaven transaction in 2022.
PFE’s Acquisitions Complement Internal R&D
Seagen, Metsera and Biohaven are the most significant strategic acquisitions in recent years. These acquisitions are turning out to be transformative opportunities for the company. Padcev, added from Seagen, contributed almost $2 billion to Pfizer’s total revenues in the first nine months of 2026, up 38% on an operational basis.
Biohaven has also been a strategically important addition for Pfizer. Year to date, Nurtec revenues have risen 29% to $11.3 billion, driven by demand growth.
Overall, revenues from Pfizer’s acquired products grew 37% operationally in the third quarter.
The November 2025 acquisition of obesity drugmaker Metsera added novel clinical-stage incretin and amylin programs, which are expected to generate billions of dollars in peak sales. A key candidate added from the Metsera deal is berobenatide.
Berobenatide is being developed for weekly and monthly dosing for obesity and obesity-related conditions, including knee osteoarthritis and obstructive sleep apnea. Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. However, in the obesity space, Pfizer lags behind leaders like Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) .
The currently available and highly popular weight loss GLP therapies, Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, are weekly injections. On the other hand, Pfizer’s berobenatide starts off as a weekly injection and then switches to a monthly injection. Berobenatide is designed for monthly maintenance dosing.
Will Pfizer's New and Acquired Drugs Fuel Future Growth?
Overall, Pfizer's new and acquired products are gradually changing its growth story from one heavily influenced by COVID-19 revenues to a more diversified business driven by oncology, specialty medicines, vaccines and migraine treatments.
Pfizer expects its recently launched and acquired products and a strong pipeline to help it return to growth from 2029 onward. Pfizer expects a risk-adjusted high single-digit revenue CAGR toward the end of the decade — from year-end 2028 through year-end 2033.
Newer products are becoming increasingly important to the company's long-term growth, although their gains have not yet translated into strong overall revenue growth.
PFE’s Price Performance, Valuation and Estimates
Pfizer’s stock has risen 12.9% so far this year compared with an increase of 24.2% for the industry.
From a valuation standpoint, Pfizer appears attractive relative to the industry. Going by the price/earnings ratio, Pfizer’s shares currently trade at 9.45 forward earnings, significantly lower than 19.50 for the industry but slightly above the stock’s five-year mean of 9.25. The stock is also trading below most large drugmakers like Lilly, Novo Nordisk, AstraZeneca, AbbVie, J&J and others.
The Zacks Consensus Estimate for 2026 earnings per share has risen from $2.95 to $3.01, while that for 2027 has risen from $2.95 to $2.96 over the past 30 days.
Pfizer has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.